CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 10 enrolled
Drug / intervention
Anastrozoledrug
Likely dose
Anastrozole 1mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01004744
NCT01004744N/ACompleted
CompareCT.gov

Feasibility of Pre-Surgical Intervention Studies for Evaluating Targeted Therapies for Breast Cancer

Columbia University·interventional·Posted Oct 30, 2009·Updated Jan 11, 2021

In Brief

A clinical study evaluating Anastrozole for Invasive Breast Cancer. Completed, enrolled 10 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the feasibility of a short term administration of a targeted therapy (i.e., anastrozole) in women with newly diagnosed early invasive or non invasive breast cancer during the interval between their breast biopsy and surgery. Anastrozole is a form of hormonal therapy which is part of the standard treatment for hormone sensitive breast cancer in postmenopausal women. This clinical model is being used to evaluate the biologic effects of this drug on a specific molecular pathway called the PI3K/AKT signaling pathway.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInvasive Breast Cancer
CountriesUnited States
CollaboratorsAvon Foundation

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 30, 2009
Enrollment StartJul 1, 2007
Primary CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 16.7 years ago

Interventions

Anastrozoledrug

1mg PO daily for two weeks prior to scheduled surgery